Imperial College London
Portrait Picture

Peter Openshaw - Professor of Experimental Medicine

Faculty of Medicine, National Heart & Lung Institute

Proconsul, Professor of Experimental Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 3854p.openshaw Website CV

 
 
//

Assistant

 

Ms Gale Lewis +44 (0)20 7594 0944

 
//

Location

 

353Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Arch:2021:10.1101/2021.06.18.21259072,
author = {Arch, BN and Kovacs, D and Scott, JT and Jones, AP and Harrison, EM and Rosala-Hallas, A and Gamble, CG and Openshaw, PJM and Baillie, JK and Semple, MG},
doi = {10.1101/2021.06.18.21259072},
title = {Evaluation of the effectiveness of remdesivir in severe COVID-19 using observational data from a prospective national cohort study},
url = {http://dx.doi.org/10.1101/2021.06.18.21259072},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Remdesivir has been evaluated in clinical trial populations, but there is a sparsity of evidence evaluating effectiveness in general populations.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Adults eligible to be treated with remdesivir, requiring oxygen but not ventilated, were identified from UK patients hospitalised with COVID-19. Patients treated with remdesivir within 24h of hospitalisation were compared with propensity-score matched controls; estimates of effectiveness were calculated for short-term outcomes (14-day mortality, 28-day mortality, time-to-recovery among others) using multivariable modelling.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>9,278 out of 39,330 patients satisfied eligibility criteria. 1,549 patients were identified as ‘treated’ and matched with 4,964 controls. Patients were 62% male, mean (SD) age 63.1 (15.6) years, 80% ‘White’ ethnicity, and symptomatic for a median of 6 days prior to baseline. There was no statistically significant benefit of remdesivir at 14 days in terms of mortality or clinical status; there were signals of effectiveness in time-to-recovery after day 9, and a reduction in 28-day mortality.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In a real-world setting, initiation of remdesivir within 24h of hospitalisation in conjunction with standard of care was not associated with a benefit at 14 days but supports clinical trial evidence of a potential reduction in 28-day mortality.</jats:p></jats:sec>
AU  - Arch,BN
AU  - Kovacs,D
AU  - Scott,JT
AU  - Jones,AP
AU  - Harrison,EM
AU  - Rosala-Hallas,A
AU  - Gamble,CG
AU  - Openshaw,PJM
AU  - Baillie,JK
AU  - Semple,MG
DO  - 10.1101/2021.06.18.21259072
PY  - 2021///
TI  - Evaluation of the effectiveness of remdesivir in severe COVID-19 using observational data from a prospective national cohort study
UR  - http://dx.doi.org/10.1101/2021.06.18.21259072
ER  -
Download